HHS awards $37.5M for Xofluza tablets, securing a 2-year supply for public health preparedness

Contract Overview

Contract Amount: $37,485,000 ($37.5M)

Contractor: Genentech USA, Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2025-09-26

End Date: 2027-09-29

Contract Duration: 733 days

Daily Burn Rate: $51.1K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: PROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS

Place of Performance

Location: SOUTH SAN FRANCISCO, SAN MATEO County, CALIFORNIA, 94080

State: California Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $37.5 million to GENENTECH USA, INC for work described as: PROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS Key points: 1. Contract value appears reasonable for a 2-year supply of a critical pharmaceutical. 2. Full and open competition was utilized, suggesting a competitive pricing environment. 3. Potential risk indicators include reliance on a single manufacturer for a specific drug. 4. The contract supports national health security by ensuring access to antiviral medication. 5. This procurement falls within the broader pharmaceutical manufacturing sector for public health. 6. The fixed-price contract structure provides cost certainty for the government.

Value Assessment

Rating: good

The contract value of $37.5 million for a two-year supply of Xofluza (baloxavir marboxil) tablets seems aligned with market expectations for specialized pharmaceuticals. While direct comparisons are difficult without proprietary pricing data, the award amount is consistent with the typical cost of antiviral medications procured for strategic stockpiles. The firm-fixed-price structure helps mitigate cost escalation risks for the government over the contract period. Benchmarking against similar government procurements for influenza antivirals would provide further context on value for money.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that multiple vendors had the opportunity to bid. The specific number of bidders is not provided, but the use of this procurement method generally fosters price discovery and encourages competitive offers. This approach is designed to ensure the government obtains the best possible value by leveraging market forces. The solicitation likely included detailed specifications for the drug, dosage, and delivery timelines to ensure fair evaluation of all proposals.

Taxpayer Impact: Full and open competition is beneficial for taxpayers as it typically leads to lower prices and a wider selection of qualified suppliers, maximizing the efficient use of public funds.

Public Impact

The primary beneficiaries are the U.S. population, who gain access to a critical antiviral medication during public health emergencies. The services delivered include the procurement and supply of 40mg and 80mg Xofluza tablets. The geographic impact is national, ensuring availability across the United States through the Strategic National Stockpile. Workforce implications are minimal in terms of direct government employment but support jobs within the pharmaceutical manufacturing and distribution sectors.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Dependence on a single supplier for a critical medication could pose a supply chain risk if manufacturing is disrupted.
The long-term effectiveness and need for this specific antiviral may change with evolving public health threats and medical advancements.

Positive Signals

The contract ensures a consistent supply of a key antiviral medication for national health security.
The firm-fixed-price agreement provides budget certainty and protects against price increases.
Awarding through full and open competition suggests a competitive process that likely secured a fair price.

Sector Analysis

This contract falls within the pharmaceutical preparation manufacturing sector, a critical component of the healthcare industry focused on producing medicines. The market for antiviral drugs, particularly those used for pandemic preparedness, is significant, driven by government stockpiling initiatives and public health concerns. Comparable spending benchmarks exist for other antiviral medications and vaccines procured by agencies like HHS and the Department of Defense for strategic reserves. The size of this award is moderate within the context of large-scale pharmaceutical procurements.

Small Business Impact

The data indicates this contract was not set aside for small businesses (ss: false, sb: false). As a procurement for a specific, branded pharmaceutical, it is likely that only the original manufacturer or authorized distributors could fulfill the requirements. Therefore, subcontracting opportunities for small businesses within this specific award are unlikely, though the prime contractor may engage small businesses for other support services not directly related to drug manufacturing or supply.

Oversight & Accountability

Oversight for this contract will likely be managed by the Office of Assistant Secretary for Preparedness and Response (ASPR) within HHS. Accountability measures are embedded in the contract terms, including delivery schedules and quality specifications. Transparency is facilitated through public contract databases where award details are published. The Inspector General for HHS would have jurisdiction to investigate any potential fraud, waste, or abuse related to this procurement.

Related Government Programs

Strategic National Stockpile
Antiviral Drug Procurement
Influenza Preparedness Programs
Public Health Emergency Countermeasures

Risk Flags

Supply Chain Concentration
Drug Resistance Potential
Long-Term Efficacy Uncertainty

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $37.5 million to GENENTECH USA, INC. PROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS

Who is the contractor on this award?

The obligated recipient is GENENTECH USA, INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $37.5 million.

What is the period of performance?

Start: 2025-09-26. End: 2027-09-29.

What is the track record of Genentech USA, Inc. in fulfilling government pharmaceutical contracts?

Genentech USA, Inc., a subsidiary of Roche, has a history of supplying pharmaceuticals to various government entities. While specific details on past government contracts for Xofluza are not publicly itemized in this dataset, the company is a major player in the pharmaceutical industry with established manufacturing and distribution capabilities. Their experience in producing and delivering complex medications suggests a capacity to meet government requirements. Further analysis would involve reviewing historical contract performance data, any past performance evaluations, and any documented issues or successes in prior government engagements to fully assess their track record for this specific type of procurement.

How does the awarded price compare to the typical market price for Xofluza (baloxavir marboxil)?

Determining the precise market price comparison for Xofluza (baloxavir marboxil) is challenging without access to proprietary pricing agreements and retail pharmacy data. Government contracts often negotiate volume discounts that may differ from commercial prices. The $37.5 million award for a two-year supply suggests an average annual cost of approximately $18.75 million. This figure needs to be contextualized by the quantity of tablets procured, which is not specified. However, given that Xofluza is a relatively new antiviral medication, its price point is generally higher than older, generic alternatives. The firm-fixed-price nature of the contract provides cost certainty, but a detailed value-for-money assessment would require benchmarking against similar government procurements or analyzing the cost per treatment course.

What are the primary risks associated with relying on a single manufacturer for this antiviral medication?

The primary risk associated with relying on a single manufacturer, Genentech USA, Inc. in this case, for Xofluza is supply chain vulnerability. Any disruption at the manufacturing facility, issues with raw material sourcing, or logistical challenges faced by the sole supplier could lead to shortages. This is particularly concerning for a medication intended for public health preparedness, where consistent availability is critical during emergencies. Diversification of suppliers or maintaining robust inventory levels are common strategies to mitigate such risks. Additionally, dependence on one supplier might limit negotiating leverage for future price reductions or contract renewals.

How effective is Xofluza (baloxavir marboxil) compared to other antivirals used for influenza treatment and prophylaxis?

Xofluza (baloxavir marboxil) represents a different class of influenza antiviral compared to neuraminidase inhibitors like oseltamivir (Tamiflu) and zanamivir (Relenza). It works by inhibiting the cap-dependent endonuclease of the influenza virus polymerase complex. Clinical studies have shown Xofluza to be effective in reducing the duration of flu symptoms and preventing complications, often with a single-dose regimen, which is a key advantage. However, concerns have been raised regarding the development of resistance, particularly in certain patient populations or with specific strains. Its efficacy relative to other antivirals can depend on the specific influenza strain circulating, patient factors, and treatment timing. Public health preparedness strategies often involve stockpiling multiple types of antivirals to ensure broad coverage against different strains and to mitigate resistance risks.

What is the historical spending pattern for antiviral medications by HHS for preparedness purposes?

HHS, primarily through agencies like the Office of the Assistant Secretary for Preparedness and Response (ASPR), has a history of significant spending on antiviral medications for the Strategic National Stockpile (SNS). This spending fluctuates based on perceived threats, the development of new countermeasures, and the expiration of existing stockpiled drugs. Historically, major procurements have included drugs like oseltamivir (Tamiflu) and zanamivir (Relenza). More recently, spending has expanded to include newer antivirals like Xofluza, reflecting advancements in medical countermeasures. Annual spending can range from tens to hundreds of millions of dollars, depending on the specific needs and the scale of preparedness initiatives. This contract for Xofluza fits within that established pattern of investing in pharmaceutical stockpiles to ensure national health security.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Roche Holding AG

Address: 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $74,970,000

Exercised Options: $74,970,000

Current Obligation: $37,485,000

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36F79723D0219

IDV Type: FSS

Timeline